GO
Loading...

Enter multiple symbols separated by commas

Celgene Corp

More

  • June 29- Celgene Corp said it would invest about $1 billion in Juno Therapeutics Inc to partner in the development and marketing of immunotherapies for the treatment of cancer and autoimmune diseases. Celgene will pay Juno about $150 million upfront and buy about 10 percent of Juno's shares at $93 each, almost double of Juno's closing price on Monday.

  • June 29- Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday. Shares of Juno were up 61 percent in...

  • June 29- Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday. Shares of Juno were up 61 percent in...

  • Lightning Round: Huge deals ahead for this group Wednesday, 17 Jun 2015 | 7:59 PM ET
    Mad Money Lightning Round

    Jim Cramer sees that this group is ready for some major deals, as he gives his take on caller favorite stocks.

  • As tech stocks stall, these names may break out Wednesday, 10 Jun 2015 | 1:55 PM ET

    Technology, one of the hottest areas in the six-year bull market has hit a standstill in 2015. Here are the stocks that could buck the trend.

  • After-hours buzz: Five Below, FireEye & more Wednesday, 3 Jun 2015 | 5:48 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Check out the companies making headlines after the bell Wednesday: Five Below, FireEye & more.

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • Biotech investors up big amid bubble talk Thursday, 28 May 2015 | 9:56 AM ET
    Biotech

    Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.

  • Here's how to play weak Q2 earnings season Monday, 18 May 2015 | 7:39 AM ET
    Delta Airlines planes sit at Terminal 4 at John F. Kennedy Airport in New York.

    Negative revenue growth will continue to dog investors in Q2 and Q3, analyst Mike Thompson says. Here's what to do about it.

  • This biotech stock is a bargain: Strategist Wednesday, 13 May 2015 | 2:45 PM ET
    Biotech

    Options expert Stacey Gilbert explains why Celgene is trading at a discount to its peers.

  • Investors were waiting for news that could move share prices from many bigger companies including Bristol-Meyers Squibb Co, Amgen Inc and Celgene Corp. Hot topics at the American Society of Clinical Oncology conference in Chicago will include immuno oncology and CAR-T cell therapies. Shares in Juno Therapeutics Inc, Kite Pharma Inc, BlueBird Bio Inc and...

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Jobless claims lowest since 2000. April 30- U.S. stocks, led by the Nasdaq, sold off on Thursday as Apple shares declined, and tech and biotech quarterly results disappointed. The Nasdaq biotech index dropped 3.1 percent on Thursday, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue.

  • NEW YORK, April 30- Stock markets worldwide posted a second straight session of losses on Thursday after more weak earnings reports, with all three major U.S. indexes plunging more than 1 percent. Celgene led a fall in U.S. biotech stocks, while shares of Harman International Industries fell 7 percent after the maker of audio systems cut its 2015 profit forecast.

  • April 30- U.S. stocks sold off on Thursday, led by a drop in the Nasdaq, as Apple shares declined and results in tech and biotech names disappointed. The Nasdaq biotech index dropped 3.1 percent, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue. Apple was down 2.7 percent at $125.15 and was the biggest drag on the Dow, S&P 500...

  • And that kind of colored the statement more hawkish for the Fed, "said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama. The Nasdaq biotech index dropped 3.2 percent, led by a 3.9 percent fall in Celgene, which reported lower-than-expected quarterly revenue. The company limited the availability of the Apple Watch after a key...

  • *Apple and Celgene weigh on Nasdaq, S&P 500. April 30- Wall Street was lower in midday trading on Thursday as Apple weighed on major indexes and investors digested a mixed batch of economic data. Apple fell as much as 2.5 percent to $125.45 and was the biggest drag on the Dow, S&P 500 and the Nasdaq.

  • NEW YORK, April 30- Stock markets worldwide stumbled for a second straight day on Thursday after more weak earnings reports, while the dollar trimmed losses after hitting fresh nine-week lows. Weak quarterly earnings from Celgene led a fell in U.S. biotech shares, while shares of Harman International Industries fell over 7 percent after the maker of audio...

  • US STOCKS-Wall St opens lower as Apple, Celgene weigh Thursday, 30 Apr 2015 | 10:39 AM ET

    *Apple and Celgene weigh on Nasdaq, S&P 500. April 30- Wall Street opened lower on Thursday as Apple weighed on the major indexes and Celgene led a fall in biotech stocks, more than offsetting encouraging economic data. The company limited availability of the Apple Watch after a key component supplied by a Chinese company was found to be defective, according to the...

  • April 30- U.S. biotechnology company Celgene Corp posted a lower-than-expected quarterly revenue, hit by a stronger dollar, but said the dollar would not hurt full-year sales and profit more that it had already forecast. Celgene in late January had forecast 2015 adjusted profit of $4.60- $4.75 per share, on net product sales of $9.0- $9.5 billion, including a near...